National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment
https://doi.org/10.14341/DM20143129-133
Abstract
In June 2014, the national experts on diabetes mellitus discussed the opportunities to improve the efficacy and outcomes of diabetes treatment using the strategy of patient-oriented care in diabetes. Insulin degludec (Tresiba?) is a new basal ultra-long-acting insulin analogue with a flat, stable glucose-lowering profile, ultra-long duration of action (>=42 h) and less within-patient day-to-day variability in glucose-lowering effect compared with currently available basal insulins. In the clinical trial programme, insulin degludec showed a similar glycaemic control compared with insulin glargine using the same insulin dose, but with a lower risk of hypoglycaemia and a greater flexibility in the time of dosing on a daily basis, when needed. Thus, the use of insulin degludec in routine clinical practice provides an effective and improved treatment for type 1 and 2 diabetes. The simple algorithm titration of insulin degludec offers the opportunity to personalise treatment regimens according to the needs of each patient.
Keywords
Supporting agencies: Novo Nordisk
About the Author
Gagik Radikovich Galstyan
Endocrinology Research Centre, Moscow; Sechenov First Moscow State Medical University, Moscow
Russian Federation
Competing Interests: Профессор Галстян Г.Р. руководит отделением диабетической стопы ФГБУ ЭНЦ, принимает участие в экспертных советах, международных клинических исследованиях, а также читает лекции от компаний Astra Zeneka, Boeringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi, Servier, Takeda.
Russian Federation
MD, PhD
Head of the Department of Diabetic Foot, Diabetes Institute, Endocrinilogy Research Centre
Professor, Endocrinology and Diabetology Department of the Pediatric Faculty, Sechenov First Moscow State Medical University
Competing Interests: Профессор Галстян Г.Р. руководит отделением диабетической стопы ФГБУ ЭНЦ, принимает участие в экспертных советах, международных клинических исследованиях, а также читает лекции от компаний Astra Zeneka, Boeringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, Sanofi, Servier, Takeda.
References
1. Evans ML, Sharplin P, Owens DR, Chamberlain GH, Longman AJ, McEwan P. Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database. British Journal of Diabetes & Vascular Disease. 2010; 10(4):178-182. doi: 10.1177/1474651410370659
2. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005;22(6):749-755. doi: 10.1111/j.1464-5491.2005.01501.x
3. Галстян ГР, Брод М. Нарушение дозирования инсулина и частота гипогликемий, купируемых самостоятельно пациентами с сахарным диабетом 2-го типа на фоне лечения базальными аналогами инсулина: результаты исследования GAPP2 в России. Сборник тезисов VI Всероссийского диабетологического конгресса «Сахарный диабет в XXI веке - время объединения усилий»,2013. [Galstyan GR, Brod M. Narushenie dozirovaniya insulina i chastota gipoglikemiy, kupiruemykh samostoyatel'no patsientami s sakharnym diabetom 2-go tipa na fone lecheniya bazal'nymi analogami insulina: rezul'taty issledovaniya GAPP2 v Rossii. In: Sbornik tezisov VI Vserossiyskogo diabetologicheskogo kongressa «Sakharnyy diabet v XXI veke - vremya ob’edineniya usiliy». Moscow; 2013.]
4. Brod M, Rana A, Barnett AH. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin 2012;28(12):1947-1958. doi: 10.1185/03007995.2012.743457
5. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012;14(9):859-864. doi: 10.1111/j.1463-1326.2012.01627.x
6. Ratner RE, Gough SCL, Mathieu C, Del Prato S, Bode B, Mersebach H, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2012;15(2):175-184. doi: 10.1111/dom.12032
7. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (6-й выпуск). Сахарный диабет. 2013;(1s):1-121. [Dedov I, Shestakova M, Aleksandrov A, Galstyan G, Grigoryan O, Esayan R, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;(1S):1-120.] doi: 10.14341/DM20131S1-121
8. Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco AM, Rothman J. Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Adv Ther 2013;30(6):607-622. doi: 10.1007/s12325-013-0036-1
9. International Diabetes Federation. Fact Sheet Diabetes and cardiovascular disease (CVD). 2011. Available from: http://www.idf.org/node/1191?unode=FCC1DD60-2C39-4D3C-A3C0-85247F1678F3
10. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. The Lancet 2009;373(9677):1765-1772. doi: 10.1016/S0140-6736(09)60697-8
11. Food and Drug Administration. . Guidance for Industry: Diabetes Mellitus — Evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US Department of Health and Human Services; 2008. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
12. Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. European Medicines Agency; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf
13. Endocrinologic and Metabolic Drugs Advisory Committee Meeting . FDA briefing document: NDA 203313 and NDA 203314 (insulin degludec and insulin degludec/insulin aspart. 2012. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf
Review
For citations:
Galstyan G.R. National advisory board on diabetes mellitus: unsolved issues and new opportunities for diabetes treatment. Diabetes mellitus. 2014;17(3):129-133. (In Russ.) https://doi.org/10.14341/DM20143129-133
Views:
712
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
